search results for

refine results

sort by

Date
Relevance

result type

Articles
Video

Wires
Press Releases

Bayer, Monsanto tout jobs, investment pledge to Trump, but analysts question how much is new

After a meeting with President-elect Donald Trump, Bayer and Monsanto pledged jobs and investment, but is this spending new? Analysts have their doubts.

Source: CNBC.com

Bayer pledges billions in US investments

According to Trump's transition team, Bayer will commit to $8 billion in new research and development jobs in the U.S. CNBC's Meg Tirrell reports.

Source: CNBC.com

Collaboration in a world where everything is connected

Technology has the potential to answer our biggest questions, solve some of our toughest challenges and help us better understand the world around us.

Source: CNBC.com

Closing Bell Exchange: Whole new world in technology

Discussing the current state of the markets with with Meg Green, Meg Green & Associates; Keith Bliss, Cuttone & Co.; and Holly Liss, BTIG.

Source: CNBC.com

Gilead CEO: M&A is top of mind for us this year

John Milligan, Gilead president and CEO, speaks to CNBC's Meg Tirrell about potential M&A, drug-pricing pressure under President-elect Donald Trump and the company's hepatitis C drugs.

Source: CNBC.com

Mylan CEO: Trump a very business-minded, solution-oriented individual

Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing under President-elect Donald Trump as he pushes to bring drug prices down.

Source: CNBC.com

Mylan CEO: EpiPen started a much-needed conversation in health care

Mylan CEO Heather Bresch speaks to CNBC's Meg Tirrell about the future of EpiPen pricing.

Source: CNBC.com

Sarepta Therapeutics CEO says drug launch is 'going very well' as shares rally 38% this month

Dr. Ed Kaye gives an update on Sarepta Therapeutics in an exclusive interview with CNBC's Meg Tirrell.

Source: CNBC.com

PRO Uncut: Alnylam CEO John Maraganore

Alnylam CEO John Maraganore joins CNCB's Meg Tirrell to discuss his outlook for the biotech sector.

Source: CNBC.com

Editas CEO: Our goal is to repair broken genes at the level of DNA

Katrine Bosley, Editas CEO, speaks to CNBC's Meg Tirrell about gene editing and the future of disease treatment.

Source: CNBC.com